Literature DB >> 18598993

Mechanisms of action of infliximab in inflammatory bowel disease: an anti-inflammatory multitasker.

S Danese1.   

Abstract

The pro-inflammatory cytokine tumor necrosis factor-alpha (TNF-alpha) plays a central role in mucosal inflammation and is a key mediator in the inflammatory cascade in both Crohn's disease (CD) and ulcerative colitis (UC). Infliximab, a monoclonal antibody against TNF-alpha has been proved highly effective in the clinical management of both forms of IBD. Aim of this paper is to review the mechanisms of action of infliximab in IBD.

Entities:  

Mesh：

Substances：

Year:  2008        PMID： 18598993     DOI： 10.1016/S1590-8658(08)60530-7

Source DB:  PubMed          Journal:  Dig Liver Dis        ISSN： 1590-8658            Impact factor:   4.088


  18 in total

Review 1.  State-of-the-art medical prevention of postoperative recurrence of Crohn's disease.

Authors:  Dario Sorrentino
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2013-05-07       Impact factor: 46.802

2.  Early diagnosis and treatment of postoperative endoscopic recurrence of Crohn's disease: partial benefit by infliximab--a pilot study.

Authors:  Dario Sorrentino; Giovanni Terrosu; Alberto Paviotti; Marco Geraci; Claudio Avellini; Giorgio Zoli; Walter Fries; Silvio Danese; Pietro Occhipinti; Tiziano Croatto; Dimitra Zarifi
Journal:  Dig Dis Sci       Date:  2012-01-18       Impact factor: 3.199

Review 3.  Promising biological therapies for ulcerative colitis: A review of the literature.

Authors:  Hirotada Akiho; Azusa Yokoyama; Shuichi Abe; Yuichi Nakazono; Masatoshi Murakami; Yoshihiro Otsuka; Kyoko Fukawa; Mitsuru Esaki; Yusuke Niina; Haruei Ogino
Journal:  World J Gastrointest Pathophysiol       Date:  2015-11-15

Review 4.  Reproducing the human mucosal environment ex vivo: inflammatory bowel disease as a paradigm.

Authors:  Kenneth D Swanson; Evangelos Theodorou; Efi Kokkotou
Journal:  Curr Opin Gastroenterol       Date:  2018-11       Impact factor: 3.287

5.  Maintenance treatment with infliximab for the management of Crohn's disease in adults.

Authors:  Renato Caviglia; Ivo Boskoski; Michele Cicala
Journal:  Biologics       Date:  2009-07-13

6.  An increased Bax/Bcl-2 ratio in circulating inflammatory cells predicts primary response to infliximab in inflammatory bowel disease patients.

Authors:  Hamid Asadzadeh Aghdaei; Azade Amini Kadijani; Dario Sorrentino; Alireza Mirzaei; Shabnam Shahrokh; Hedieh Balaii; Marco Geraci; Mohammad Reza Zali
Journal:  United European Gastroenterol J       Date:  2018-05-02       Impact factor: 4.623

7.  Effects of Anti-Inflammatory Treatment and Surgical Intervention on Endothelial Glycocalyx, Peripheral and Coronary Microcirculatory Function and Myocardial Deformation in Inflammatory Bowel Disease Patients: A Two-Arms Two-Stage Clinical Trial.

Authors:  Charilaos Triantafyllou; Maria Nikolaou; Ignatios Ikonomidis; Giorgos Bamias; Dimitrios Kouretas; Ioanna Andreadou; Maria Tsoumani; John Thymis; Ioannis Papaconstantinou
Journal:  Diagnostics (Basel)       Date:  2021-05-30

Review 8.  Clinical use and mechanisms of infliximab treatment on inflammatory bowel disease: a recent update.

Authors:  Yuan Guo; Nonghua Lu; Aiping Bai
Journal:  Biomed Res Int       Date:  2013-01-21       Impact factor: 3.411

Review 9.  Immunomodulatory and anti-inflammatory effects of chondroitin sulphate.

Authors:  Patrick du Souich; Antonio G García; Josep Vergés; Eulàlia Montell
Journal:  J Cell Mol Med       Date:  2009-06-11       Impact factor: 5.310

10.  Malignant melanoma of the ileo-anal pouch anastomosis after restorative proctocolectomy for ulcerative colitis: report of a case.

Authors:  Philipp Lingohr; Thomas Galetin; Hanno Matthaei; Eberhard Straub; Azin Jafari; Edwin Bölke; Jörg C Kalff; Karl-Heinz Vestweber
Journal:  Eur J Med Res       Date:  2013-11-04       Impact factor: 2.175
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.